<DOC>
	<DOCNO>NCT02223481</DOCNO>
	<brief_summary>This study seek determine whether terbogrel effective treatment primary pulmonary hypertension ( PPH ) compare efficacy safety placebo .</brief_summary>
	<brief_title>Safety Efficacy Terbogrel Patients With Primary Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Primary pulmonary hypertension New York Health Association ( NYHA ) chronic heart failure ( CHF ) functional class IIIII Ability walk &gt; = 50 meter 6 minute walk test Resting mean pulmonary artery pressure &gt; 25 mmHg Mean right atrial pressure &lt; = 20 mmHg Pulmonary capillary wedge pressure &lt; = 15 mmHg Cardiac index &gt; 2.5 L/min2 SvO2 sit . &gt; 63 % Male female least 18 year old Signed write informed consent Secondary pulmonary hypertension due lung systemic disease Pregnant nursing woman , woman childbearing potential use adequate method birth control Concurrent systematic use aspirin , aspirin like drug , nonsteroidal antiinflammatory drug ( NSAIDs ) Surgery bleed gastrointestinal , genitourinary tract , cerebrum retina within past 6 week History bleed diathesis platelet count le 70,000/mm3 Exercise limited factor fatigue exertional dyspnea , arthritis , claudication , angina , chronic obstructive pulmonary disease , bronchial asthma Myocardial infarction , stroke , transient ischemic attack within precede six month Systolic blood pressure &lt; 90 mmHg &gt; 180 mmHg , diastolic blood pressure &gt; 110 mmHg Known drug alcohol dependency within one year entry study Known hypersensitivity component study formulation , epoprostenol , nitric oxide , adenosine Psychiatric illness condition , opinion principal investigator , may interfere study participation , compliance , element protocol Participation evaluation investigational drug within past 30 day Portal hypertension cirrhosis liver Congenital heart disease e.g. , atrial septal defect ; patent foramen ovale exclude patient study Appetite suppressant fenfluramine , dexfenfluramine , inhibitor serotonin uptake know associated primary pulmonary hypertension , receive within 3 month entry study HIV positive Vasodilators . Patients receive Cachannel blocker study unless medication start prior study patient stable dose least one month prior entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>